Can Innovative Biotech Startups Revolutionise Gene Therapy Manufacturing Processes?

• Biotech startup Autolomous aims at revolutionising the gene cell therapy manufacturing process by providing pragmatic digital solutions.
• Autolomous caters to both ends, by focusing on the manufacturing process and seeking to integrate with other support systems.
• The company’s bespoke software platform, autoloMATE®, ensures high configurability letting clients build their own workflows.
• The platform is developed in line with numerous global regulatory guidelines, assuring full adherence to legal requirements.”

Seamlessly merging biotechnology, healthcare, IT, manufacturing, and the pharmaceutical industry, UK-based startup Autolomous is set to transform the way gene and cell therapies are manufactured. This London startup leverages technology and innovation to streamline advanced treatment creation, offering unparalleled solutions in the biotechnology sector.

AutoloMATE®, the enterprise-level, cloud-native software platform offered by Autolomous, enables end-to-end solutions for gene therapy manufacturing activities. AutoloMATE® not only concentrates on the manufacturing process but also integrates with various support systems making it a comprehensive solution.

AutoloMATE® is a game changer as it enables resource scheduling, management of electronic batch records, insights reporting as well as review and release activities. This level of flexibility and end-to-end solution makes the platform stand out in the gene therapy manufacturing industry. Furthermore, the AutoloMATE® software has been designed to seamlessly adhere to regulatory standards – US FDA, EU EMA & UK MHRA and GAMP5 methodology, ensuring its clients meet all legal and regulatory requirements.

AutoloMATE’s high configurability lets clients build their own workflows, providing a personalised user experience and promoting efficient work processes. The company further strengthens its value proposition through multiple ISO certifications—ISO 27001:2013 (information security), ISO 9001:2015 (quality management), and ISO 14001:2015 (environmental management). These certifications signify Autolomous’s commitment to maintaining high standards in diverse areas.

The momentum that Autolomous is building in the biotech industry is impressive. With a focus on innovative manufacturing processes and end-to-end solutions, the startup holds a lot of potential for future growth. As the industry continues to embrace advanced technology in its operations, Autolomous’s role as a digital solution provider is poised to become even more significant.

In conclusion, the London-based startup Autolomous is stretching the boundaries of what is possible in gene therapy manufacturing. By integrating technology and biotechnology seamlessly, Autolomous is moving the industry towards a future where advanced therapies will be attainable and expeditious. To stay in touch and keep up-to-date with Autolomous, follow them on Twitter and LinkedIn or visit their website.